Pharma Class Action

     SAN FRANCISCO – Shareholders claim Clovis Oncology goosed its share price with false and misleading reports about its rociletinib drug, and shares fell from $69.19 to $30.24 on Nov. 16 when the truth came out, in Federal Court.

%d bloggers like this: